ReviewMediators of inflammation2015
Role of Sphingolipids in the Pathobiology of Lung Inflammation.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 135 citations in OpenAlex.
- Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders.Scientific reports · 2021Trial
- Analysis of the Plasma Metabolome after Trauma, Novel Circulating Sphingolipid Signatures, and In-Hospital Outcomes.Journal of the American College of Surgeons · 2021Trial
- Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin DMetabolism: clinical and experimental · 2017Trial
- Investigating the exhaled lipid biomarkers among e-cigarette users compared to non-smokers.Lipids in health and disease · 2026Article
- Plasma Ceramides Levels in Severe COVID-19 Disease: Correlations with Survival.Open forum infectious diseases · 2026Article
- Association of plasma ceramide with stroke-associated pneumonia in acute ischemic stroke.Frontiers in immunology · 2026Article
- Lipid profiling in nontuberculous mycobacterial pulmonary disease based on geospatial locations and disease severity.ERJ open research · 2026Article
- Porcine respiratory disease complex induces pulmonary fibrosis related to the aberrant sphingolipid metabolism.International journal of experimental pathology · 2025Article
- Redox Imbalance in Cystic Fibrosis: The Multifaceted Role of Oxidative Stress.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipidomic profiling of the cerebrospinal fluid in moyamoya angiopathy patients.Orphanet journal of rare diseases · 2025Article
- TheMicrobiology (Reading, England) · 2025Article
- New perspectives on the progression of pulmonary fibrosis: the cascade from aberrant microvascular endothelial cell activation to fibrosis.Frontiers in medicine · 2025Review
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- ThebioRxiv : the preprint server for biology · 2024Article
- Untargeted Blood Lipidomics Analysis in Critically Ill Pediatric Patients with Ventilator-Associated Pneumonia: A Pilot Study.Metabolites · 2024Article
- Sphingolipid changes in mouse brain and plasma after mild traumatic brain injury at the acute phases.Lipids in health and disease · 2024Article
- Lipids in Equine Airway Inflammation: An Overview of Current Knowledge.Animals : an open access journal from MDPI · 2024Review
- Metabolomic profiles of sleep-disordered breathing are associated with hypertension and diabetes mellitus development.Nature communications · 2024Article
- LiLA: lipid lung-based ATLAS built through a comprehensive workflow designed for an accurate lipid annotation.Communications biology · 2024Article
- New Therapeutic Options in Pulmonal Diseases: Sphingolipids and Modulation of Sphingolipid Metabolism.Handbook of experimental pharmacology · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingolipid bioactivities in the respiratory airways and the roles of the proteins that handle them have been extensively investigated. Gas or inhaled particles or microorganisms come into contact with mucus components, epithelial cells, blood barrier, and immune surveillance within the airways. Lung structure and functionality rely on a complex interplay of polar and hydrophobic structures forming the surfactant layer and governing external-internal exchanges, such as glycerol-phospholipids sphingolipids and proteins. Sphingolipids act as important signaling mediators involved in the control of cell survival and stress response, as well as secreted molecules endowed with inflammation-regulatory activities. Most successful respiratory infection and injuries evolve in the alveolar compartment, the critical lung functional unit involved in gas exchange. Sphingolipid altered metabolism in this compartment is closely related to inflammatory reaction and ceramide increase, in particular, favors the switch to pathological hyperinflammation. This short review explores a few mechanisms underlying sphingolipid involvement in the healthy lung (surfactant production and endothelial barrier maintenance) and in a selection of lung pathologies in which the impact of sphingolipid synthesis and metabolism is most apparent, such as acute lung injury, or chronic pathologies such as cystic fibrosis and chronic obstructive pulmonary disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.